Literature DB >> 24906479

Ahead of its time? Reflecting on New Zealand's Pharmac following its 20th anniversary.

Robin Gauld1.   

Abstract

New Zealand's Pharmaceutical Management Agency (Pharmac) was created in 1993. Unusual in international terms, Pharmac's objective is to work within a fixed budget while ensuring the New Zealand public receives an adequate range of government-subsidised medicines. Following its 20th anniversary, this article reflects on Pharmac's development and role within the New Zealand health system, various changes over time to the agency's scope and activities, its performance and its present challenges.

Mesh：

Substances：

Year:  2014        PMID： 24906479     DOI： 10.1007/s40273-014-0178-2

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


  17 in total

1.  The sorry saga of the statins in New Zealand--pharmacopolitics versus patient care.

Authors:  Evan Begg; Andrew Sidwell; Sharon Gardiner; Gary Nicholls; Russell Scott
Journal:  N Z Med J       Date:  2003-03-14

2.  Access to new medicines in New Zealand compared to Australia.

Authors:  Michael Wonder; Richard Milne
Journal:  N Z Med J       Date:  2011-11-25

3.  New Zealand's post-2008 health system reforms: toward re-centralization of organizational arrangements.

Authors:  Robin Gauld
Journal:  Health Policy       Date:  2012-04-12       Impact factor: 2.980

4.  "Tough but fair"? The active management of the New Zealand drug benefits scheme by an independent Crown agency.

Authors:  Peter Davis
Journal:  Aust Health Rev       Date:  2004-11-08       Impact factor: 1.990

5.  PHARMAC and the statin debacle.

Authors:  Chris Ellis; Harvey White
Journal:  N Z Med J       Date:  2006-06-23

6.  Applying Programme Budgeting Marginal Analysis in the health sector: 12 years of experience.

Authors:  Rachel Grocott
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2009-04       Impact factor: 2.217

7.  How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.

Authors:  Deborah Gleeson; Ruth Lopert; Papaarangi Reid
Journal:  Health Policy       Date:  2013-08-30       Impact factor: 2.980

8.  Assessing the value for money of pharmaceuticals in New Zealand--PHARMAC's approach to cost-utility analysis.

Authors:  Rachel Grocott; Scott Metcalfe; Paul Alexander; Rachel Werner
Journal:  N Z Med J       Date:  2013-07-12

9.  PHARMAC looks great value for money--an Australian perspective.

Authors:  Linda J Cobiac
Journal:  N Z Med J       Date:  2012-07-29

10.  "Price management" and its impact on hospital pharmaceutical expenditure and the availability of medicines in New Zealand hospitals.

Authors:  June M Tordoff; Pauline T Norris; David M Reith
Journal:  Value Health       Date:  2008-05-16       Impact factor: 5.725
View more
  2 in total

1.  Comment on "ahead of its time? Reflecting on New Zealand's Pharmac following its 20th anniversary" : clarification from PHARMAC: PHARMAC takes no particular distributive approach (utilitarian or otherwise).

Authors:  Scott Metcalfe; Rachel Grocott; Dilky Rasiah
Journal:  Pharmacoeconomics       Date:  2014-10       Impact factor: 4.981

2.  Differences in health care spending and utilization among older frail adults in high-income countries: ICCONIC hip fracture persona.

Authors:  Irene Papanicolas; Jose F Figueroa; Andrew J Schoenfeld; Kristen Riley; Olukorede Abiona; Mina Arvin; Femke Atsma; Enrique Bernal-Delgado; Nicholas Bowden; Carl Rudolf Blankart; Sarah Deeny; Francisco Estupiñán-Romero; Robin Gauld; Philip Haywood; Nils Janlov; Hannah Knight; Luca Lorenzoni; Alberto Marino; Zeynep Or; Anne Penneau; Kosta Shatrov; Mai Stafford; Onno van de Galien; Kees van Gool; Walter Wodchis; Ashish K Jha
Journal:  Health Serv Res       Date:  2021-08-14       Impact factor: 3.402
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.